Scientists launch major study to unravel mysteries of rare brain infection PML
NCT ID NCT01730131
First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 11 times
Summary
This study follows 700 people with progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. Researchers will collect blood, spinal fluid, and brain scans over time to understand how the disease progresses. No treatment is given; the goal is to learn more about PML to improve diagnosis and future care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could improve how doctors diagnose and monitor PML, and may point toward future treatment targets.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly help participants, and results may take years to influence care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 700 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2012
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Primary clinical for participants that have PML or at risk for PML and community sample/healthy relatives for healthy volunteers.
- Ages
-
2 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* PML Patients INCLUSION CRITERIA: 1. Suspected or confirmed PML 2. MRI compatible with PML 3. Able to participate in the studies and follow-up required by the protocol 4. At least 2 years old EXCLUSION CRITERIA: 1. Significant condition, which in the judgment of the principal investigator, would make participation in the diagnostic and research parts of evaluation impossible or risky 2. Medical contraindication to MRI (i.e., devices such as a cardiac pacemaker or infusion pump, other metallic implants, metallic foreign objects, body piercings that cannot be removed) 3. Pregnancy 4. Inability to provide informed consent, either directly or via legally authorized representative (LAR) 5. Unwillingness to consent for collection of biological samples or their cryopreservation Control Patients at Risk for PML INCLUSION CRITERIA: 1. Able to participate in the studies and follow-up required by the protocol 2. At least 2 years old 3. Impaired immune function from any cause and considered at risk for PML (i.e.-history of hematological malignancy, chronic inflammatory disease, history of treatment with immune suppressive or immunomodulatory therapies, primary or acquired immunodeficiency syndromes) EXCLUSION CRITERIA: 1. Significant condition, which in the judgment of the principal investigator, would make participation in the diagnostic and research parts of evaluation impossible or risky 2. Medical contraindication to MRI (i.e., devices such as a cardiac pacemaker or infusion pump, other metallic implants, metallic foreign objects, body piercings that cannot be removed) 3. Pregnancy 4. Inability to provide informed consent, either directly or via legally authorized representative (LAR) 5. Unwillingness to consent for collection of biological samples or their cryopreservation Healthy Volunteers INCLUSION CRITERIA: 1. Able to participate in the studies and follow-up required by the protocol 2. At least 18 years old EXCLUSION CRITERIA: 1. Impaired immune function (i.e.-history of hematological malignancy, chronic inflammatory disease, history of treatment with immune suppressive or immunomodulatory therapies, primary or acquired immunodeficiency syndromes) 2. Significant condition, which in the judgment of the principal investigator, would make participation in the diagnostic and research parts of evaluation impossible or risky 3. Medical contraindication to MRI (i.e., devices such as a cardiac pacemaker or infusion pump, other metallic implants, metallic foreign objects, body piercings that cannot be removed) 4. Pregnancy 5. Inability to provide informed consent, either directly or via legally authorized representative (LAR) 6. Unwillingness to consent for collection of biological samples or their cryopreservation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Progressive multifocal leukoencephalopathy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Rare brain infection risk under scrutiny for multiple sclerosis drug ozanimod
- Can a cancer drug wake up immune cells to beat HIV-Related infections?
- Could a common steroid prevent a deadly complication in AIDS patients?
- Could immune checkpoint drugs tame a deadly brain virus?
- Experimental drug targets deadly brain virus in small trial
- Scientists uncover how PML virus hides from immune system